RainSure Exhibits Hematology and Cell Analysis Technologies at MEDICA 2026

By LabMedica International staff writers
Posted on 17 Nov 2026

RainSure Scientific (San Jose, CA, USA) is showcasing its molecular diagnostics and life sciences technologies at MEDICA 2026, taking place November 16–19 in Düsseldorf, Germany. At Hall 3, Stand B20, the company is highlighting its hematology testing solutions, OMNIS Flow full-spectrum flow cytometer, OmniPlex dPx multi-omics platform, and UriFind urine-based cancer detection assay. These technologies support applications ranging from molecular disease monitoring and cellular analysis to cancer detection and cell and gene therapy research.

Among the featured solutions is RainSure's hematology portfolio, which combines KindStar's targeted next-generation sequencing (NGS) panels with digital PCR (dPCR) technology. The portfolio covers six disease categories, including myeloid leukemia, chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), lymphoma, and plasma cell dyscrasias. A key component is the FDA 510(k)-cleared FastPlex BCR-ABL (p210) %IS digital PCR Kit, designed for molecular monitoring of treatment response in patients with previously diagnosed Philadelphia chromosome-positive chronic myeloid leukemia.


Image: RainSure Scientific is showcasing its new lineup of platforms at MEDICA 2026 (Photo courtesy of RainSure Scientific)

RainSure is also presenting the OMNIS Flow full-spectrum flow cytometer, equipped with five lasers and supporting 79 colors for high-parameter cellular analysis. The system enables detailed characterization of cell populations for research applications. Another featured technology is the OmniPlex dPx platform, which simultaneously detects proteins and nucleic acids to support characterization of adeno-associated viruses (AAVs), lipid nanoparticles (LNPs), and extracellular vesicles (EVs) in cell and gene therapy research and development.

The company is also highlighting UriFind, developed by AnchorDx, a non-invasive urine-based DNA methylation test intended for the early detection and auxiliary diagnosis of urothelial carcinomas, including cancers of the bladder, renal pelvis, and ureter. The assay identifies ONECUT2 and VIM epigenetic biomarkers using a random urine sample of approximately 100 mL. According to RainSure, UriFind has received FDA Breakthrough Device designation, which facilitates regulatory development and review but does not constitute marketing authorization. Together, these technologies reflect RainSure's focus on precision diagnostics and life sciences research.


Latest Medica 2026 News